Abstract |
We report the final analysis of the PROLONG study on ofatumumab maintenance in relapsed chronic lymphocytic leukemia (CLL). In all, 480 patients with CLL in complete or partial remission after second- or third-line treatment were randomized 1:1 to ofatumumab (300 mg first week, followed by 1000 mg every 8 weeks for up to 2 years) or observation. Median follow-up duration was 40.9 months. Median progression-free survival was 34.2 and 16.9 months for ofatumumab and observation arms, respectively, (hazard ratio, 0.55 [95% confidence interval, 0.43-0.70]; P < 0.0001). Median time to next treatment for ofatumumab and observation arms, respectively, was 37.4 and 27.6 months (0.72 [0.57-0.91]; P = 0.0044). Overall survival was similar in both arms; median was not reached (0.99 [0.72-1.37]). Grade ≥ 3 adverse events occurred in 62% and 51% of patients in ofatumumab and observation arms, respectively, the most common being neutropenia (23% and 10%), pneumonia (13% and 12%) and febrile neutropenia (6% and 4%). Up to 60 days after the last treatment, four deaths were reported in the ofatumumab arm versus six in the observation arm, none considered related to ofatumumab. Ofatumumab maintenance significantly prolonged progression-free survival in patients with relapsed CLL and was well tolerated.
|
Authors | Marinus van Oers, Lukas Smolej, Mario Petrini, Fritz Offner, Sebastian Grosicki, Mark-David Levin, Jaclyn Davis, Hiya Banerjee, Tommaso Stefanelli, Petra Hoever, Christian Geisler |
Journal | Blood cancer journal
(Blood Cancer J)
Vol. 9
Issue 12
Pg. 98
(12 04 2019)
ISSN: 2044-5385 [Electronic] United States |
PMID | 31801940
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
- ofatumumab
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized
(administration & dosage, adverse effects, therapeutic use)
- Antineoplastic Agents, Immunological
(administration & dosage, adverse effects, therapeutic use)
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
(diagnosis, drug therapy, mortality)
- Maintenance Chemotherapy
- Male
- Middle Aged
- Recurrence
- Retreatment
- Treatment Outcome
|